Real-World Insights on Tarlatamab Administration in Community Oncology Practices

Tarlatamab Administration in Community Oncology: A Real-World Perspective

A recent study presented by OneOncology during the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid sheds light on the real-world application of tarlatamab, a treatment for advanced-stage small cell lung cancer (ES-SCLC). This retrospective study included 90 patients receiving care from community oncology practices, aiming to evaluate the safety and efficacy of tarlatamab outside traditional inpatient settings.

Study Overview

Tarlatamab is a bispecific T-cell engager that specifically targets delta-like ligand 3 (DLL3) as well as CD3, facilitating the immune system's ability to attack cancer cells. Historically, the treatment required patients to stay in a health care environment for observation due to potential side effects such as cytokine release syndrome (CRS) and neurotoxicity. As a result, many patients faced significant burdens, including lengthy hospital stays. However, with updated guidelines from the U.S. Food and Drug Administration (FDA) reducing the recommended observation time after the initial dosing from 24 hours to just 6-8 hours, community oncology practices are now more equipped to deliver this therapy in an outpatient setting.

Key Findings

The study's findings are promising, with only 46% of patients experiencing any degree of CRS, the majority being low-grade. Notably, only 1% of patients had grade 3 or higher events of CRS, and 2% experienced grade 3 or higher neurotoxicity. Furthermore, the report indicated that outpatient administration resulted in the lowest rates of CRS among the different treatment models observed. Among various treatment settings—outpatient, inpatient, and hybrid (a combination of both)—the outpatient cohort exhibited only grade 1 CRS, confirming its relative safety in this setting.

Of the 90 patients analyzed, three required intensive care, demonstrating the overall manageable risk profile of tarlatamab in outpatient settings. Importantly, there were no readmissions among any of the patients, indicating a high level of treatment tolerance.

Patient Cohorts and Their Characteristics

The study categorizes patients into three groups based on their treatment setting: outpatient, inpatient, and hybrid. Patients in the hybrid model displayed a greater disease burden at baseline, revealing correlations between more extensive metastases and higher incidences of CRS and neurotoxicity. This insight suggests that baseline characteristics may significantly inform patient selection for outpatient tarlatamab administration.

Expert Insights

Trevor Feinstein, M.D., lead author of the study, expressed optimism about these findings, stating, "The real-world results give us greater confidence that tarlatamab can be delivered outside the traditional inpatient setting in appropriately selected patients." Similarly, Wade Iams, M.D., emphasized the importance of these results in expanding access to novel therapies within community oncology.

Conclusions and Next Steps

While these findings underscore the feasibility and safety of administering tarlatamab in outpatient oncology practices, the study is retrospective, prompting a need for more extensive, prospective studies to firmly establish criteria for patient selection. The study's authors acknowledged limitations, including the reliance on medical records for data collection and the relatively small sample size. They concluded that further exploration into patient characteristics and long-term outcomes is essential to enhance treatment protocols moving forward.

As the oncology landscape continues to evolve, the insights gathered from such real-world studies pave the way for improved patient care strategies, democratizing access to advanced cancer treatments like tarlatamab. This pioneering approach by OneOncology holds potential for redefining outpatient cancer therapy and improving patient outcomes in diverse community settings.